Medicine
Genetic Basis of Inherited Cancer Syndromes and Screening Implications
Quick fact
A woman with a BRCA1 mutation faces up to a 72% lifetime risk of breast cancer and up to a 44% risk of ovarian cancer, compared to about 12% and 1.3% in the general population.
Why this is interesting
Why do some families seem to face cancer generation after generation? The answer lies in a single letter change in a gene, passed down quietly until it erupts as a tumor.
Read the full explanation
Understanding Genetic Basis of Inherited Cancer Syndromes and Screening Implications
Most cancers are sporadic, but about 5-10% are inherited. These inherited syndromes are caused by permanent mutations in genes that are present from birth in every cell. These mutations are usually in tumor suppressor genes or DNA repair genes. The inheritance is typically autosomal dominant, meaning that inheriting one mutated copy of the gene greatly increases cancer risk, even though that mutation is recessive at the cellular level. For example, in hereditary breast and ovarian cancer, mutations in BRCA1 or BRCA2 hinder the repair of DNA double-strand breaks. In Lynch syndrome, mutations in mismatch repair genes like MLH1 or MSH2 lead to an accumulation of replication errors. The key is that these mutations are 'first hits' that make cells more vulnerable to further genetic damage, greatly accelerating the process of cancer formation.
A deeper explanation
The mechanism underlying inherited cancer syndromes is the 'two-hit hypothesis' or the fact that these mutations are in genes that guard the genome. In the case of tumor suppressors, the germline mutation provides the first hit; a somatic mutation later in life in the other allele eliminates the protective function, allowing a clone to develop. For DNA repair genes, even one deficient allele can impair repair efficiency because of haploinsufficiency or because loss of the second allele is often the initiating event. This loss of genomic stability means that cells accumulate mutations at a faster rate, increasing the probability that oncogenes will be activated and tumor suppressors inactivated. The screening implications are clear: individuals with these mutations need to be monitored more frequently and often starting at a younger age. For example, women with BRCA mutations might begin mammography and MRI screening at age 25, whereas mainstream screening begins at 40 or later. For Lynch syndrome, colonoscopies are recommended every 1-2 years beginning at age 20-25, whereas the general population starts at 45. The understanding of the specific gene involved also guides preventive options like prophylactic mastectomy or oophorectomy for BRCA carriers and aspirin chemoprophylaxis for Lynch. Thus, knowing the genetic basis is not just academic; it directly determines the screening schedule and management plan for at-risk individuals and their families.